BioMedica's TroVax trial adopted by NCRN

UK-based gene therapy company Oxford BioMedica says that a Phase III trial of its novel immunotherapy TroVax, which is assessing the agent as a treatment for renal cancer, has been adopted by the National Cancer Research Network. The company explained that the decision by the NCRN, the part of the UK National Health Services that provides infrastructure support for cancer drug studies, means that the program can now be carried out at several of the network's clinical centers, thereby expediting patient recruitment.

Oxford BioMedica added that, in its research, the NCRN concluded that TroVax should be supported because it has the potential to improve patient care. The firm went on to say that NCRN involvement does not impact upon its commercial rights, and that it is under no financial obligations.